Get to know our clinical trials
Trial of subcutaneous amlitelimab in participants aged 12 years or older with moderate to severe atopic dermatitis.
THE OBJECTIVE OF THE EFC17600 STUDY IS TO EVALUATE THE TREATMENT RESPONSE AND SAFETY OF TWO (2) DOSING REGIMENS OF AMLITELIMAB IN PARTICIPANTS WITH MODERATE TO SEVERE AD.
Status
In recruitment
headquarters
Pamplona
Technical Summary
- PHASE III, MULTINATIONAL, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, 48-WEEK, PHASE III EXTENSION STUDY TO EVALUATE THE TREATMENT RESPONSE AND SAFETY OF TWO DOSING REGIMENS OF AMLITELIMAB ADMINISTERED AS MONOTHERAPY BY SUBCUTANEOUS INJECTION IN PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS IMMUNOTHERAPY
- Code EudraCT: 2023-508096-36
- Protocol number: EFC17600
- Promoter: Sanofi-Aventis S.A.
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.